These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21699390)

  • 1. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols.
    Alexander BD; Winkler TP; Shi S; Dodds Ashley ES; Hickey AJ
    Pharm Dev Technol; 2011; 16(6):577-82. PubMed ID: 21699390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.
    Shi S; Ashley ES; Alexander BD; Hickey AJ
    AAPS PharmSciTech; 2009; 10(1):129-37. PubMed ID: 19189220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
    Kamalaporn H; Leung K; Nagel M; Kittanakom S; Calvieri B; Reithmeier RA; Coates AL
    Pediatr Pulmonol; 2014 Jun; 49(6):574-80. PubMed ID: 23843366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
    Shah SP; Misra A
    Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ; Vulto AG; Van Etten EW
    J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
    Furco A; Mouchet B; Carbonnelle M; Vallerand H
    Rev Mal Respir; 2001 Jun; 18(3):309-13. PubMed ID: 11468594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Oct; 54(10):1342-7. PubMed ID: 19796414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deposition of amphotericin B aerosols in pulmonary aspergilloma.
    Diot P; Rivoire B; Le Pape A; Lemarie E; Dire D; Furet Y; Breteau M; Smaldone GC
    Eur Respir J; 1995 Aug; 8(8):1263-8. PubMed ID: 7489788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.
    Roth C; Gebhart J; Just-Nübling G; von Eisenhart-Rothe B; Beinhauer-Reeb I
    Infection; 1996; 24(5):354-60. PubMed ID: 8923045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study.
    Van Dyke RE; Nikander K
    Respir Care; 2007 Feb; 52(2):184-90. PubMed ID: 17261207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer.
    Johnson JC; Waldrep JC; Guo J; Dhand R
    Respir Care; 2008 Dec; 53(12):1703-8. PubMed ID: 19025706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulization and
    Mišík O; Kejíková J; Cejpek O; Malý M; Jugl A; Bělka M; Mravec F; Lízal F
    Mol Pharm; 2024 Apr; 21(4):1848-1860. PubMed ID: 38466817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
    Fauvel M; Farrugia C; Tsapis N; Gueutin C; Cabaret O; Bories C; Bretagne S; Barratt G
    Int J Pharm; 2012 Oct; 436(1-2):106-10. PubMed ID: 22814222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization.
    Nasr M; Nawaz S; Elhissi A
    Int J Pharm; 2012 Oct; 436(1-2):611-6. PubMed ID: 22842623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.
    Nasr M; Najlah M; D'Emanuele A; Elhissi A
    Int J Pharm; 2014 Jan; 461(1-2):242-50. PubMed ID: 24275446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study.
    Sayed NEE; Abdelrahman MA; Abdelrahim MEA
    Pulm Pharmacol Ther; 2021 Oct; 70():102054. PubMed ID: 34280581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
    Waldrep JC; Berlinski A; Dhand R
    J Aerosol Med; 2007; 20(3):310-9. PubMed ID: 17894537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Studies of the Nebulized Delivery of Liposomal Amphotericin B.
    Kothari S; Kefalos SG; Hages ND; Corcoran TE; Husain S
    J Aerosol Med Pulm Drug Deliv; 2022 Dec; 35(6):307-312. PubMed ID: 36516401
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of aerosol output from various nebulizer/compressor combinations.
    Reisner C; Katial RK; Bartelson BB; Buchmeir A; Rosenwasser LJ; Nelson HS
    Ann Allergy Asthma Immunol; 2001 May; 86(5):566-74. PubMed ID: 11379809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.